A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours.

Howard A BurrisJordan BerlinTobias ArkenauGregory M CoteMartijn P LolkemaJordi Ferrer-PlayanAnup KalapurJayaprakasam BolleddulaGiuseppe LocatelliThomas GoddemeierIoannis GounarisJohann de Bono

Published in: British journal of cancer (2024)

GOV: NCT02278250.

Keyphrases

phase ii study
clinical trial
squamous cell carcinoma
dna damage response
oxidative stress
dna damage
open label